Trial
NCT04188509
Open-Label Extension of Voxelotor
Phase IIITERMINATEDSAFETYConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
Sickle Cell Disease
Intervention
Voxelotor
Why stopped
Emerging clinical data evaluated by Pfizer and shared with regulatory authorities indicates that the risk profile of voxelotor in people with SCD exceeds the benefits observed in previously generated global research and requires further assessment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-13